Primary Outcomes for Resuscitation Science Studies A Consensus Statement From the American Heart Association

The guidelines presented in this consensus statement are intended to serve researchers, clinicians, reviewers, and regulators in the selection of the most appropriate primary outcome for a clinical trial of cardiac arrest therapies. The American Heart Association guidelines for the treatment of card...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circulation (New York, N.Y.) N.Y.), 2011-11, Vol.124 (19), p.2158-2177
Hauptverfasser: BECKER, Lance B, AUFDERHEIDE, Tom P, MERCHANT, Raina M, O'CONNOR, Robert E, MELTZER, David O, HOLM, Margo B, LONGSTRETH, William T, HALPERIN, Henry R, GEOCADIN, Romergryko G, CALLAWAY, Clifton W, LAZAR, Ronald M, DONNINO, Michael W, NADKARNI, Vinay M, ABELLA, Benjamin S, ADRIE, Christophe, BERG, Robert A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2177
container_issue 19
container_start_page 2158
container_title Circulation (New York, N.Y.)
container_volume 124
creator BECKER, Lance B
AUFDERHEIDE, Tom P
MERCHANT, Raina M
O'CONNOR, Robert E
MELTZER, David O
HOLM, Margo B
LONGSTRETH, William T
HALPERIN, Henry R
GEOCADIN, Romergryko G
CALLAWAY, Clifton W
LAZAR, Ronald M
DONNINO, Michael W
NADKARNI, Vinay M
ABELLA, Benjamin S
ADRIE, Christophe
BERG, Robert A
description The guidelines presented in this consensus statement are intended to serve researchers, clinicians, reviewers, and regulators in the selection of the most appropriate primary outcome for a clinical trial of cardiac arrest therapies. The American Heart Association guidelines for the treatment of cardiac arrest depend on high-quality clinical trials, which depend on the selection of a meaningful primary outcome. Because this selection process has been the subject of much controversy, a consensus conference was convened with national and international experts, the National Institutes of Health, and the US Food and Drug Administration. The Research Working Group of the American Heart Association Emergency Cardiovascular Care Committee nominated subject leaders, conference attendees, and writing group members on the basis of their expertise in clinical trials and a diverse perspective of cardiovascular and neurological outcomes (see the online-only Data Supplement). Approval was obtained from the Emergency Cardiovascular Care Committee and the American Heart Association Manuscript Oversight Committee. Preconference position papers were circulated for review; the conference was held; and postconference consensus documents were circulated for review and comments were invited from experts, conference attendees, and writing group members. Discussions focused on (1) when after cardiac arrest the measurement time point should occur; (2) what cardiovascular, neurological, and other physiology should be assessed; and (3) the costs associated with various end points. The final document underwent extensive revision and peer review by the Emergency Cardiovascular Care Committee, the American Heart Association Science Advisory and Coordinating Committee, and oversight committees. There was consensus that no single primary outcome is appropriate for all studies of cardiac arrest. The best outcome measure is the pairing of a time point and physiological condition that will best answer the question under study. Conference participants were asked to assign an outcome to each of 4 hypothetical cases; however, there was not complete agreement on an ideal outcome measure even after extensive discussion and debate. There was general consensus that it is appropriate for earlier studies to enroll fewer patients and to use earlier time points such as return of spontaneous circulation, simple "alive versus dead," hospital mortality, or a hemodynamic parameter. For larger studies, a lo
doi_str_mv 10.1161/CIR.0b013e3182340239
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3719404</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>911944054</sourcerecordid><originalsourceid>FETCH-LOGICAL-c340t-1d30bb5b679d87c4bce47ea34bd2c32077fca100953801ca6280ff76d273e2203</originalsourceid><addsrcrecordid>eNpdkUtv1TAQhS0EoreFf4CQN4hVil-J4w3S1RV9SJWKWlhbzmRCjRK72A4S_x6XeymP1cjjb87M0SHkFWennHf83e7y5pQNjEuUvBdSMSHNE7LhrVCNaqV5SjaMMdNoKcQROc75a312UrfPyZHgpjOMsw2ZPya_uPSDXq8F4oKZTjHRG8xrBl9c8THQW_AYAOltWUdfiS3dxZAxVKb2XMEFQ6FnKS603CHdLpg8uEAv0KVCtzlH8L-UXpBnk5szvjzUE_L57MOn3UVzdX1-udteNVBtlIaPkg1DO3TajL0GNQAqjU6qYRQgBdN6Asert1b2jIPrRM-mSXej0BKFYPKEvN_r3q_DgiPU85Kb7f3eqo3O239_gr-zX-J3KzU3iqkq8PYgkOK3FXOxi8-A8-wCxjVbwyunWPtAqj0JKeaccHrcwpl9yMnWnOz_OdWx139f-Dj0O5gKvDkALoObp-QC-PyHa4Uwsu3lT-LfnbI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>911944054</pqid></control><display><type>article</type><title>Primary Outcomes for Resuscitation Science Studies A Consensus Statement From the American Heart Association</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Journals@Ovid Complete</source><creator>BECKER, Lance B ; AUFDERHEIDE, Tom P ; MERCHANT, Raina M ; O'CONNOR, Robert E ; MELTZER, David O ; HOLM, Margo B ; LONGSTRETH, William T ; HALPERIN, Henry R ; GEOCADIN, Romergryko G ; CALLAWAY, Clifton W ; LAZAR, Ronald M ; DONNINO, Michael W ; NADKARNI, Vinay M ; ABELLA, Benjamin S ; ADRIE, Christophe ; BERG, Robert A</creator><creatorcontrib>BECKER, Lance B ; AUFDERHEIDE, Tom P ; MERCHANT, Raina M ; O'CONNOR, Robert E ; MELTZER, David O ; HOLM, Margo B ; LONGSTRETH, William T ; HALPERIN, Henry R ; GEOCADIN, Romergryko G ; CALLAWAY, Clifton W ; LAZAR, Ronald M ; DONNINO, Michael W ; NADKARNI, Vinay M ; ABELLA, Benjamin S ; ADRIE, Christophe ; BERG, Robert A ; American Heart Association Emergency Cardiovascular Care Committee ; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation</creatorcontrib><description>The guidelines presented in this consensus statement are intended to serve researchers, clinicians, reviewers, and regulators in the selection of the most appropriate primary outcome for a clinical trial of cardiac arrest therapies. The American Heart Association guidelines for the treatment of cardiac arrest depend on high-quality clinical trials, which depend on the selection of a meaningful primary outcome. Because this selection process has been the subject of much controversy, a consensus conference was convened with national and international experts, the National Institutes of Health, and the US Food and Drug Administration. The Research Working Group of the American Heart Association Emergency Cardiovascular Care Committee nominated subject leaders, conference attendees, and writing group members on the basis of their expertise in clinical trials and a diverse perspective of cardiovascular and neurological outcomes (see the online-only Data Supplement). Approval was obtained from the Emergency Cardiovascular Care Committee and the American Heart Association Manuscript Oversight Committee. Preconference position papers were circulated for review; the conference was held; and postconference consensus documents were circulated for review and comments were invited from experts, conference attendees, and writing group members. Discussions focused on (1) when after cardiac arrest the measurement time point should occur; (2) what cardiovascular, neurological, and other physiology should be assessed; and (3) the costs associated with various end points. The final document underwent extensive revision and peer review by the Emergency Cardiovascular Care Committee, the American Heart Association Science Advisory and Coordinating Committee, and oversight committees. There was consensus that no single primary outcome is appropriate for all studies of cardiac arrest. The best outcome measure is the pairing of a time point and physiological condition that will best answer the question under study. Conference participants were asked to assign an outcome to each of 4 hypothetical cases; however, there was not complete agreement on an ideal outcome measure even after extensive discussion and debate. There was general consensus that it is appropriate for earlier studies to enroll fewer patients and to use earlier time points such as return of spontaneous circulation, simple "alive versus dead," hospital mortality, or a hemodynamic parameter. For larger studies, a longer time point after arrest should be considered because neurological assessments fluctuate for at least 90 days after arrest. For large trials designed to have a major impact on public health policy, longer-term end points such as 90 days coupled with neurocognitive and quality-of-life assessments should be considered, as should the additional costs of this approach. For studies that will require regulatory oversight, early discussions with regulatory agencies are strongly advised. For neurological assessment of post-cardiac arrest patients, researchers may wish to use the Cerebral Performance Categories or modified Rankin Scale for global outcomes. Although there is no single recommended outcome measure for trials of cardiac arrest care, the simple Cerebral Performance Categories or modified Rankin Scale after 90 days provides a reasonable outcome parameter for many trials. The lack of an easy-to-administer neurological functional outcome measure that is well validated in post-cardiac arrest patients is a major limitation to the field and should be a high priority for future development.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/CIR.0b013e3182340239</identifier><identifier>PMID: 21969010</identifier><identifier>CODEN: CIRCAZ</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams &amp; Wilkins</publisher><subject>American Heart Association ; Biological and medical sciences ; Blood and lymphatic vessels ; Cardiology - standards ; Cardiology. Vascular system ; Cardiopulmonary Resuscitation - standards ; Cardiovascular system ; Consensus ; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous ; Emergency Medical Services - standards ; Heart Arrest - therapy ; Humans ; Medical sciences ; Pharmacology. Drug treatments ; United States ; Vasodilator agents. Cerebral vasodilators</subject><ispartof>Circulation (New York, N.Y.), 2011-11, Vol.124 (19), p.2158-2177</ispartof><rights>2015 INIST-CNRS</rights><rights>2011 American Heart Association, Inc. 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c340t-1d30bb5b679d87c4bce47ea34bd2c32077fca100953801ca6280ff76d273e2203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,3674,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=25229358$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21969010$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BECKER, Lance B</creatorcontrib><creatorcontrib>AUFDERHEIDE, Tom P</creatorcontrib><creatorcontrib>MERCHANT, Raina M</creatorcontrib><creatorcontrib>O'CONNOR, Robert E</creatorcontrib><creatorcontrib>MELTZER, David O</creatorcontrib><creatorcontrib>HOLM, Margo B</creatorcontrib><creatorcontrib>LONGSTRETH, William T</creatorcontrib><creatorcontrib>HALPERIN, Henry R</creatorcontrib><creatorcontrib>GEOCADIN, Romergryko G</creatorcontrib><creatorcontrib>CALLAWAY, Clifton W</creatorcontrib><creatorcontrib>LAZAR, Ronald M</creatorcontrib><creatorcontrib>DONNINO, Michael W</creatorcontrib><creatorcontrib>NADKARNI, Vinay M</creatorcontrib><creatorcontrib>ABELLA, Benjamin S</creatorcontrib><creatorcontrib>ADRIE, Christophe</creatorcontrib><creatorcontrib>BERG, Robert A</creatorcontrib><creatorcontrib>American Heart Association Emergency Cardiovascular Care Committee</creatorcontrib><creatorcontrib>Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation</creatorcontrib><title>Primary Outcomes for Resuscitation Science Studies A Consensus Statement From the American Heart Association</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description>The guidelines presented in this consensus statement are intended to serve researchers, clinicians, reviewers, and regulators in the selection of the most appropriate primary outcome for a clinical trial of cardiac arrest therapies. The American Heart Association guidelines for the treatment of cardiac arrest depend on high-quality clinical trials, which depend on the selection of a meaningful primary outcome. Because this selection process has been the subject of much controversy, a consensus conference was convened with national and international experts, the National Institutes of Health, and the US Food and Drug Administration. The Research Working Group of the American Heart Association Emergency Cardiovascular Care Committee nominated subject leaders, conference attendees, and writing group members on the basis of their expertise in clinical trials and a diverse perspective of cardiovascular and neurological outcomes (see the online-only Data Supplement). Approval was obtained from the Emergency Cardiovascular Care Committee and the American Heart Association Manuscript Oversight Committee. Preconference position papers were circulated for review; the conference was held; and postconference consensus documents were circulated for review and comments were invited from experts, conference attendees, and writing group members. Discussions focused on (1) when after cardiac arrest the measurement time point should occur; (2) what cardiovascular, neurological, and other physiology should be assessed; and (3) the costs associated with various end points. The final document underwent extensive revision and peer review by the Emergency Cardiovascular Care Committee, the American Heart Association Science Advisory and Coordinating Committee, and oversight committees. There was consensus that no single primary outcome is appropriate for all studies of cardiac arrest. The best outcome measure is the pairing of a time point and physiological condition that will best answer the question under study. Conference participants were asked to assign an outcome to each of 4 hypothetical cases; however, there was not complete agreement on an ideal outcome measure even after extensive discussion and debate. There was general consensus that it is appropriate for earlier studies to enroll fewer patients and to use earlier time points such as return of spontaneous circulation, simple "alive versus dead," hospital mortality, or a hemodynamic parameter. For larger studies, a longer time point after arrest should be considered because neurological assessments fluctuate for at least 90 days after arrest. For large trials designed to have a major impact on public health policy, longer-term end points such as 90 days coupled with neurocognitive and quality-of-life assessments should be considered, as should the additional costs of this approach. For studies that will require regulatory oversight, early discussions with regulatory agencies are strongly advised. For neurological assessment of post-cardiac arrest patients, researchers may wish to use the Cerebral Performance Categories or modified Rankin Scale for global outcomes. Although there is no single recommended outcome measure for trials of cardiac arrest care, the simple Cerebral Performance Categories or modified Rankin Scale after 90 days provides a reasonable outcome parameter for many trials. The lack of an easy-to-administer neurological functional outcome measure that is well validated in post-cardiac arrest patients is a major limitation to the field and should be a high priority for future development.</description><subject>American Heart Association</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Cardiology - standards</subject><subject>Cardiology. Vascular system</subject><subject>Cardiopulmonary Resuscitation - standards</subject><subject>Cardiovascular system</subject><subject>Consensus</subject><subject>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</subject><subject>Emergency Medical Services - standards</subject><subject>Heart Arrest - therapy</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>United States</subject><subject>Vasodilator agents. Cerebral vasodilators</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkUtv1TAQhS0EoreFf4CQN4hVil-J4w3S1RV9SJWKWlhbzmRCjRK72A4S_x6XeymP1cjjb87M0SHkFWennHf83e7y5pQNjEuUvBdSMSHNE7LhrVCNaqV5SjaMMdNoKcQROc75a312UrfPyZHgpjOMsw2ZPya_uPSDXq8F4oKZTjHRG8xrBl9c8THQW_AYAOltWUdfiS3dxZAxVKb2XMEFQ6FnKS603CHdLpg8uEAv0KVCtzlH8L-UXpBnk5szvjzUE_L57MOn3UVzdX1-udteNVBtlIaPkg1DO3TajL0GNQAqjU6qYRQgBdN6Asert1b2jIPrRM-mSXej0BKFYPKEvN_r3q_DgiPU85Kb7f3eqo3O239_gr-zX-J3KzU3iqkq8PYgkOK3FXOxi8-A8-wCxjVbwyunWPtAqj0JKeaccHrcwpl9yMnWnOz_OdWx139f-Dj0O5gKvDkALoObp-QC-PyHa4Uwsu3lT-LfnbI</recordid><startdate>20111108</startdate><enddate>20111108</enddate><creator>BECKER, Lance B</creator><creator>AUFDERHEIDE, Tom P</creator><creator>MERCHANT, Raina M</creator><creator>O'CONNOR, Robert E</creator><creator>MELTZER, David O</creator><creator>HOLM, Margo B</creator><creator>LONGSTRETH, William T</creator><creator>HALPERIN, Henry R</creator><creator>GEOCADIN, Romergryko G</creator><creator>CALLAWAY, Clifton W</creator><creator>LAZAR, Ronald M</creator><creator>DONNINO, Michael W</creator><creator>NADKARNI, Vinay M</creator><creator>ABELLA, Benjamin S</creator><creator>ADRIE, Christophe</creator><creator>BERG, Robert A</creator><general>Lippincott Williams &amp; Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20111108</creationdate><title>Primary Outcomes for Resuscitation Science Studies A Consensus Statement From the American Heart Association</title><author>BECKER, Lance B ; AUFDERHEIDE, Tom P ; MERCHANT, Raina M ; O'CONNOR, Robert E ; MELTZER, David O ; HOLM, Margo B ; LONGSTRETH, William T ; HALPERIN, Henry R ; GEOCADIN, Romergryko G ; CALLAWAY, Clifton W ; LAZAR, Ronald M ; DONNINO, Michael W ; NADKARNI, Vinay M ; ABELLA, Benjamin S ; ADRIE, Christophe ; BERG, Robert A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c340t-1d30bb5b679d87c4bce47ea34bd2c32077fca100953801ca6280ff76d273e2203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>American Heart Association</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Cardiology - standards</topic><topic>Cardiology. Vascular system</topic><topic>Cardiopulmonary Resuscitation - standards</topic><topic>Cardiovascular system</topic><topic>Consensus</topic><topic>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</topic><topic>Emergency Medical Services - standards</topic><topic>Heart Arrest - therapy</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>United States</topic><topic>Vasodilator agents. Cerebral vasodilators</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BECKER, Lance B</creatorcontrib><creatorcontrib>AUFDERHEIDE, Tom P</creatorcontrib><creatorcontrib>MERCHANT, Raina M</creatorcontrib><creatorcontrib>O'CONNOR, Robert E</creatorcontrib><creatorcontrib>MELTZER, David O</creatorcontrib><creatorcontrib>HOLM, Margo B</creatorcontrib><creatorcontrib>LONGSTRETH, William T</creatorcontrib><creatorcontrib>HALPERIN, Henry R</creatorcontrib><creatorcontrib>GEOCADIN, Romergryko G</creatorcontrib><creatorcontrib>CALLAWAY, Clifton W</creatorcontrib><creatorcontrib>LAZAR, Ronald M</creatorcontrib><creatorcontrib>DONNINO, Michael W</creatorcontrib><creatorcontrib>NADKARNI, Vinay M</creatorcontrib><creatorcontrib>ABELLA, Benjamin S</creatorcontrib><creatorcontrib>ADRIE, Christophe</creatorcontrib><creatorcontrib>BERG, Robert A</creatorcontrib><creatorcontrib>American Heart Association Emergency Cardiovascular Care Committee</creatorcontrib><creatorcontrib>Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BECKER, Lance B</au><au>AUFDERHEIDE, Tom P</au><au>MERCHANT, Raina M</au><au>O'CONNOR, Robert E</au><au>MELTZER, David O</au><au>HOLM, Margo B</au><au>LONGSTRETH, William T</au><au>HALPERIN, Henry R</au><au>GEOCADIN, Romergryko G</au><au>CALLAWAY, Clifton W</au><au>LAZAR, Ronald M</au><au>DONNINO, Michael W</au><au>NADKARNI, Vinay M</au><au>ABELLA, Benjamin S</au><au>ADRIE, Christophe</au><au>BERG, Robert A</au><aucorp>American Heart Association Emergency Cardiovascular Care Committee</aucorp><aucorp>Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Primary Outcomes for Resuscitation Science Studies A Consensus Statement From the American Heart Association</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>2011-11-08</date><risdate>2011</risdate><volume>124</volume><issue>19</issue><spage>2158</spage><epage>2177</epage><pages>2158-2177</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><coden>CIRCAZ</coden><abstract>The guidelines presented in this consensus statement are intended to serve researchers, clinicians, reviewers, and regulators in the selection of the most appropriate primary outcome for a clinical trial of cardiac arrest therapies. The American Heart Association guidelines for the treatment of cardiac arrest depend on high-quality clinical trials, which depend on the selection of a meaningful primary outcome. Because this selection process has been the subject of much controversy, a consensus conference was convened with national and international experts, the National Institutes of Health, and the US Food and Drug Administration. The Research Working Group of the American Heart Association Emergency Cardiovascular Care Committee nominated subject leaders, conference attendees, and writing group members on the basis of their expertise in clinical trials and a diverse perspective of cardiovascular and neurological outcomes (see the online-only Data Supplement). Approval was obtained from the Emergency Cardiovascular Care Committee and the American Heart Association Manuscript Oversight Committee. Preconference position papers were circulated for review; the conference was held; and postconference consensus documents were circulated for review and comments were invited from experts, conference attendees, and writing group members. Discussions focused on (1) when after cardiac arrest the measurement time point should occur; (2) what cardiovascular, neurological, and other physiology should be assessed; and (3) the costs associated with various end points. The final document underwent extensive revision and peer review by the Emergency Cardiovascular Care Committee, the American Heart Association Science Advisory and Coordinating Committee, and oversight committees. There was consensus that no single primary outcome is appropriate for all studies of cardiac arrest. The best outcome measure is the pairing of a time point and physiological condition that will best answer the question under study. Conference participants were asked to assign an outcome to each of 4 hypothetical cases; however, there was not complete agreement on an ideal outcome measure even after extensive discussion and debate. There was general consensus that it is appropriate for earlier studies to enroll fewer patients and to use earlier time points such as return of spontaneous circulation, simple "alive versus dead," hospital mortality, or a hemodynamic parameter. For larger studies, a longer time point after arrest should be considered because neurological assessments fluctuate for at least 90 days after arrest. For large trials designed to have a major impact on public health policy, longer-term end points such as 90 days coupled with neurocognitive and quality-of-life assessments should be considered, as should the additional costs of this approach. For studies that will require regulatory oversight, early discussions with regulatory agencies are strongly advised. For neurological assessment of post-cardiac arrest patients, researchers may wish to use the Cerebral Performance Categories or modified Rankin Scale for global outcomes. Although there is no single recommended outcome measure for trials of cardiac arrest care, the simple Cerebral Performance Categories or modified Rankin Scale after 90 days provides a reasonable outcome parameter for many trials. The lack of an easy-to-administer neurological functional outcome measure that is well validated in post-cardiac arrest patients is a major limitation to the field and should be a high priority for future development.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>21969010</pmid><doi>10.1161/CIR.0b013e3182340239</doi><tpages>20</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0009-7322
ispartof Circulation (New York, N.Y.), 2011-11, Vol.124 (19), p.2158-2177
issn 0009-7322
1524-4539
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3719404
source MEDLINE; American Heart Association Journals; EZB-FREE-00999 freely available EZB journals; Journals@Ovid Complete
subjects American Heart Association
Biological and medical sciences
Blood and lymphatic vessels
Cardiology - standards
Cardiology. Vascular system
Cardiopulmonary Resuscitation - standards
Cardiovascular system
Consensus
Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
Emergency Medical Services - standards
Heart Arrest - therapy
Humans
Medical sciences
Pharmacology. Drug treatments
United States
Vasodilator agents. Cerebral vasodilators
title Primary Outcomes for Resuscitation Science Studies A Consensus Statement From the American Heart Association
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T13%3A40%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Primary%20Outcomes%20for%20Resuscitation%20Science%20Studies%20A%20Consensus%20Statement%20From%20the%20American%20Heart%20Association&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=BECKER,%20Lance%20B&rft.aucorp=American%20Heart%20Association%20Emergency%20Cardiovascular%20Care%20Committee&rft.date=2011-11-08&rft.volume=124&rft.issue=19&rft.spage=2158&rft.epage=2177&rft.pages=2158-2177&rft.issn=0009-7322&rft.eissn=1524-4539&rft.coden=CIRCAZ&rft_id=info:doi/10.1161/CIR.0b013e3182340239&rft_dat=%3Cproquest_pubme%3E911944054%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=911944054&rft_id=info:pmid/21969010&rfr_iscdi=true